Match each blood-detected clone to the lesion it comes from on the scan
Blood tests tell you which tumour sub-populations are growing; scans tell you which lesions are growing. Joining the two would tell you where to biopsy or irradiate.
Tissue-of-origin methylation, lesion-specific private mutations from multi-site biopsies, and lesion volume kinetics from serial imaging could be combined in a joint model that assigns plasma clone fractions to anatomical lesions. This would let clinicians direct local therapy at the lesion carrying the expanding resistant clone without biopsying every site.
- Tumour heterogeneity and clonal evolution · A tumour is many tumours. Treatments that kill most cells leave the rest to grow back, changed.
- Metastasis is understood least and studied last · Metastasis causes about nine in ten cancer deaths but gets a small fraction of research money and almost no trials of its own.
Pages like this
not linked directly; found by shared links- IdeaTrack clones in blood with methylation patterns instead of mutations
Shares DNA methylation profiling, Tumour heterogeneity and clonal evolution, Liquid biopsy (ctDNA).
- IdeaWhole-body MRI plus blood DNA surveillance for people with Li-Fraumeni syndrome
Shares Whole-body MRI, Liquid biopsy (ctDNA).
- IdeaA urine DNA test to decide who with blood in the urine needs a camera test
- InstitutionHealthCare Global Enterprises
Shares PET/CT, Liquid biopsy (ctDNA).
- IdeaA national rapid research autopsy network for end-stage cancer
Shares Tumour heterogeneity and clonal evolution, Metastasis is understood least and studied last.
- IdeaA 28-day national pathway for people with a positive multi-cancer blood test
Shares Whole-body MRI, PET/CT.
- TermOligoprogression
Shares Tumour heterogeneity and clonal evolution, Metastasis is understood least and studied last.
- IdeaA blood test for the pre-metastatic niche
Shares Metastasis is understood least and studied last, Liquid biopsy (ctDNA).